European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf   - zoledronic acid monohydrate - fractures, bone - drugs for treatment of bone diseases - prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - zoledronic acid monohydrate - hypercalcemia - drugs for treatment of bone diseases - 4 mg / 5 ml and 4 mg / 100 ml:prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).5 mg / 100 ml:treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.treatment of paget's disease of the bone in adults.

European Union - English - EMA (European Medicines Agency)

teva generics b.v - zoledronic acid monohydrate - osteoporosis; osteitis deformans - bisphosphonates - treatment of osteoporosisin post-menopausal womenin adult menat increased risk of fracture, including those with recent low-trauma hip fracture.treatment of osteoporosis associated with long-term systemic glucocorticoid therapyin post-menopausal womenin adult menat increased risk of fracture.treatment of paget's disease of the bone in adults.

Canada - English - Health Canada

actavis pharma company - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors

Canada - English - Health Canada

actavis pharma company - zoledronic acid (zoledronic acid monohydrate) - solution - 5mg - zoledronic acid (zoledronic acid monohydrate) 5mg - bone resorption inhibitors

Canada - English - Health Canada

jamp pharma corporation - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors

Canada - English - Health Canada

pharmascience inc - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl = ca in mg/dl + 0.8 (4.0 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adver

United Kingdom - English - myHealthbox

dr. reddy’s laboratories (uk) ltd., 6 riverview road - zoledronic acid (as monohydrate) - concentrate for solution for infusion - 4 mg for 5ml - drugs affecting bone structure and mineralization, bisphosphonates - it is used for prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. and for the treatment of adult patients with tumour-induced hypercalcaemia (tih)

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - zoledronic acid, monohydrate - concentrate for solution for infusion - zoledronic acid monohydrate 4 mg - drugs for treatment of bone diseases